Lifyorli Extends Survival in Ovarian Cancer Across Taxane Groups

Updated findings from the phase 3 ROSELLA trial showed that patients with platinum-resistant ovarian cancer continued to experience an overall survival benefit with Lifyorli (relacorilant) plus Abraxane (nab-paclitaxel) regardless of their previous exposure to taxane chemotherapy, according to data presented at the 2026 ASCO Annual Meeting.

Researchers reported that patients who received the combination lived longer than those treated with Abraxane alone, with benefits observed across several patient groups, including those who had received taxane-based treatment more recently and those whose most recent treatment did not include a taxane.

Main Data That Support the Findings

At a median follow-up of 24.8 months, patients treated with Lifyorli plus Abraxane lived a median of 16.0 months compared with 11.9 months for those who received Abraxane alone.

Researchers noted that nearly all patients enrolled in the study had previously received taxane chemotherapy, making the subgroup analysis particularly important in understanding whether prior treatment history affected outcomes.

The updated analysis found that the survival benefit remained consistent regardless of how much time had passed since a patient's previous taxane treatment. Similar benefits were also observed whether a taxane had been included in a patient's most recent treatment regimen.

"Overall survival favored the relacorilant combination arm across all prespecified subgroups, including participants with a short taxane-free interval and with taxane use in the most recent regimen," said Dr. Lucy Gilbert, of the Division of Gynecologic Oncology at McGill University Health Centre in Montreal, Quebec, during the presentation.

Gilbert added that the median improvement of 4.1 months in overall survival supports the use of Lifyorli plus Abraxane as a treatment option that does not require biomarker testing before use.

The findings build on previously reported results from ROSELLA, which helped support the FDA approval of Lifyorli in combination with Abraxane in March 2026 for patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.

In addition to improving overall survival, the study previously showed that the combination helped patients live longer without their cancer growing or spreading compared with Abraxane alone.

Trial Details

ROSELLA enrolled 381 patients with platinum-resistant ovarian cancer.

Patients were randomly assigned to receive either Lifyorli plus Abraxane or Abraxane alone.

Researchers designed the study to evaluate whether adding Lifyorli to chemotherapy could improve survival outcomes for patients whose disease had become resistant to platinum-based treatment.

The current analysis focused specifically on prior taxane exposure. Taxanes are a commonly used class of chemotherapy drugs in ovarian cancer treatment, and investigators sought to determine whether previous taxane treatment affected the benefit of the Lifyorli combination.

According to the study findings, the survival advantage associated with Lifyorli plus Abraxane remained consistent regardless of a patient's prior taxane treatment history.

Safety

Investigators reported that Lifyorli plus Abraxane continued to demonstrate a favorable and manageable safety profile.

No new safety concerns emerged with longer follow-up, and the safety findings were consistent with previous reports from the trial.

"There were no relacorilant-related fatal adverse events and no cases of adrenal insufficiency," Gilbert said during the presentation.

Researchers noted that the updated safety findings further support the use of the combination as a treatment option for patients with platinum-resistant ovarian cancer.

References

1. “Overall survival subgroup analyses for prior taxane use in the phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72, APGOT-Ov10, LACOG-0223, and ANZGOG-2221/2023)” by Dr. Lucy Gilbert, et al., Journal of Clinical Oncology. Presented at the 2026 ASCO Annual Meeting; May 29-June 2, 2026; Chicago, Illinois. Abstract 5503.
2. “Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial” by Dr. Domenica Lorusso, et al., The Lancet.
3. “FDA approves relacorilant with nab-paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer,” U.S. Food and Drug Administration. March 25, 2026.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.